Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.

@article{Metz2014OmalizumabIA,
  title={Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.},
  author={Martin Metz and Tatevik Ohanyan and M K Church and Marcus Maurer},
  journal={Journal of dermatological science},
  year={2014},
  volume={73 1},
  pages={57-62}
}
BACKGROUND Omalizumab (anti-IgE) therapy is effective and safe in chronic urticaria (CU) in placebo-controlled clinical trials but real life clinical data are scarce. OBJECTIVE To better understand the effects of omalizumab in CU patients treated outside of clinical trials. METHODS In this retrospective clinical analysis, we assessed responder rates, optimal dosage, response to up-/downdosing, time to relief of symptoms, rates of return and time of relapse after omalizumab administration… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 54 extracted citations

Similar Papers

Loading similar papers…